Osang Healthcare, a company specializing in in vitro diagnostics, is embarking on the initial public offering (IPO) process.

Osang Healthcare announced, “We submitted an application for preliminary listing review to the Korea Exchange today (the 9th) for listing on KOSDAQ.”

This comes about two years after receiving a rejection notice in 2021. The lead underwriter is NH Investment & Securities.